Aclaris Therapeutics (NASDAQ:ACRS) Research Coverage Started at Cantor Fitzgerald

Cantor Fitzgerald assumed coverage on shares of Aclaris Therapeutics (NASDAQ:ACRS) in a research report report published on Tuesday morning, MarketBeat Ratings reports. The brokerage issued an overweight rating on the biotechnology company’s stock. Cantor Fitzgerald also issued estimates for Aclaris Therapeutics’ FY2025 earnings at ($0.62) EPS.

ACRS has been the topic of several other reports. Jefferies Financial Group raised Aclaris Therapeutics from a “hold” rating to a “buy” rating and upped their price target for the stock from $2.00 to $7.00 in a research note on Tuesday, November 19th. Scotiabank assumed coverage on Aclaris Therapeutics in a research note on Friday, March 7th. They issued a “sector outperform” rating and a $15.00 price target on the stock. StockNews.com cut Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, February 8th. Piper Sandler raised Aclaris Therapeutics from a “neutral” rating to an “overweight” rating and upped their price target for the stock from $3.00 to $13.00 in a research note on Monday, November 18th. Finally, Leerink Partnrs raised Aclaris Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Tuesday, November 19th. One investment analyst has rated the stock with a sell rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $11.67.

Aclaris Therapeutics Stock Up 1.3 %

Shares of ACRS stock opened at $1.57 on Tuesday. The stock has a market cap of $169.43 million, a price-to-earnings ratio of -3.02 and a beta of 0.48. The business’s fifty day moving average is $2.18 and its 200 day moving average is $2.20. Aclaris Therapeutics has a twelve month low of $0.95 and a twelve month high of $5.17.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Adage Capital Partners GP L.L.C. bought a new position in shares of Aclaris Therapeutics during the fourth quarter valued at $23,876,000. Vivo Capital LLC bought a new position in shares of Aclaris Therapeutics during the fourth quarter valued at $22,044,000. Rock Springs Capital Management LP lifted its holdings in shares of Aclaris Therapeutics by 125.3% during the fourth quarter. Rock Springs Capital Management LP now owns 6,204,309 shares of the biotechnology company’s stock valued at $15,387,000 after purchasing an additional 3,450,814 shares in the last quarter. RA Capital Management L.P. bought a new position in shares of Aclaris Therapeutics during the fourth quarter valued at $11,573,000. Finally, Janus Henderson Group PLC bought a new position in shares of Aclaris Therapeutics during the fourth quarter valued at $6,985,000. 98.34% of the stock is owned by institutional investors.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.